GLP-1RA and SGLT2 inhibitor combination therapy was associated with better cardiorenal outcomes than monotherapy among patients with type 2 diabetes. The cardiorenal benefits of sodium-glucose ...

In previous First Word columns, I discussed the effects of SGLT2 inhibitors on the kidney to prevent progression of chronic ...

SGLT2 inhibitors are a new family of agents ... Given the high importance of diabetes, the glucose homeostasis in human body has been deeply analyzed and investigated. It is characterized by ...

Use of SGLT2 inhibitors was associated with improved kidney health among a diverse multiethnic cohort of Asian adults with type 2 diabetes, researchers found in a retrospective cohort study.

The main action of SGLT2 inhibitors is the induction of glucosuria ... Parathormone; TIIDM: Type 2 diabetes mellitus. placebo HbA1c (%):/CANA: −0.70 to −0.95/PL: −0.22/SITA: −0.74 FPG ...

Sodium-glucose cotransporter-2 (SGLT2) inhibitors, a newer class of drugs used to treat diabetes, have recently been ...

Type 2 diabetes is common; it affects one in ten adults internationally and one in five adults aged 65 years or older. It is ...

A recent study conducted across public hospitals in Hong Kong highlighted the superiority of sodium-glucose cotransporter 2 ...

From 2010 to 2023, GLP-1RAs and SGLT2 inhibitors saw rising prescriptions in type 1 diabetes, particularly for patients with obesity and cardiorenal risks. Researchers found that children who ...

Mina Makar highlights AstraZeneca's commitment to advancing heart failure research and innovative therapies, addressing ...

The study’s results offer hope. By reducing the risk of heart and kidney disease, SGLT2 inhibitors may help people with type ...

If the EMA follows the CHMP’s advice, Zynquista will become the second SGLT-acting drug to be approved for use alongside insulin in type 1 diabetes after AstraZeneca’s SGLT2 inhibitor Forxiga ...